Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), exhibits robust clinical efficacy in NSCLC patients with EGFR-sensitive mutations [4, 5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.